ArticleTurkish journal of obstetrics and gynecology2026
Prognostic determinants of survival in early-stage endometrial cancer: A retrospective analysis.
Article in Turkish journal of obstetrics and gynecology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The aim of this study was to investigate prognostic determinants of survival in early-stage endometrial cancer (EC), focusing on clinicopathological parameters including histologic grade, tumor stage, myometrial invasion, lymphovascular space invasion (LVSI), and preoperative CA-125, as well as the role of adjuvant therapies in disease-free survival (DFS) and overall survival (OS). Materials and Methods: We retrospectively analyzed women treated surgically for International Federation of Gynecology and Obstetrics 2009 stage I-II EC at a tertiary center between January 2011 and January 2023. Demographic and pathological data were collected, including age, body mass index, reproductive history, menopausal status, comorbidities, tumor size, histologic subtype and grade, depth of myometrial invasion, LVSI, serum CA-125 levels, and surgical procedures. Adjuvant therapies-external beam radiotherapy, vaginal brachytherapy, and chemotherapy-were also documented. Associations between these variables and survival outcomes were assessed using Kaplan-Meier and Cox regression analyses. Results: A total of 241 women with early-stage EC were included. Median age was 57 years (range: 34-86 years). Of these, 181 (75.1%) were stage IA, 47 (19.5%) were stage IB, and 13 (5.4%) were stage II. Histologic grades were grade 1 in 44.8%, grade 2 in 39.0%, and grade 3 in 16.2%. During a median follow-up of 75 months, recurrence occurred in 4.6% of patients and mortality in 7.9% of patients. Univariate analysis showed that elevated CA-125, higher stage, and higher grade were associated with worse OS. Multivariate analysis identified histologic grade as an independent predictor of both OS and DFS. Neither adjuvant radiotherapy nor chemotherapy improved survival outcomes. Conclusion: Histologic grade was the strongest independent prognostic factor for OS and DFS in early-stage EC, surpassing tumor stage, myometrial invasion, and LVSI. These findings highlight the importance of comprehensive surgical staging, especially when high-grade tumors are detected intraoperatively, to ensure accurate risk stratification and appropriate use of adjuvant therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.